Medina Pilar, Navarro Silvia, Estellés Amparo, España Francisco
Research Center, La Fe University Hospital, Valencia, Spain.
Thromb Haemost. 2007 Sep;98(3):564-9.
The protein C anticoagulant pathway plays a crucial role as a regulator of the blood clotting cascade. Protein C is activated on the vascular endothelial cell membrane by the thrombin-thrombomodulin complex. Once formed, activated protein C (APC) down-regulates thrombin formation by inactivating factors (F)Va and FVIIIa. Endothelial protein C receptor (EPCR) is able to bind protein C and increase the rate of protein C activation. Normal APC generation depends on the precise assemblage, on the surface of endothelial cells, of thrombin, thrombomodulin, protein C and EPCR. Therefore, any change in the efficiency of this assemblage may cause reduced/increased APC generation and modify the risk of thrombosis. This review highlights the different mutations/polymorphisms reported in the EPCR gene and their association with the risk of thrombosis.
蛋白C抗凝途径作为血液凝固级联反应的调节因子发挥着关键作用。蛋白C在血管内皮细胞膜上被凝血酶-血栓调节蛋白复合物激活。一旦形成,活化蛋白C(APC)通过使因子(F)Va和FVIIIa失活来下调凝血酶的形成。内皮蛋白C受体(EPCR)能够结合蛋白C并提高蛋白C的激活速率。正常的APC生成取决于凝血酶、血栓调节蛋白、蛋白C和EPCR在内皮细胞表面的精确组装。因此,这种组装效率的任何变化都可能导致APC生成减少/增加,并改变血栓形成的风险。本综述重点介绍了EPCR基因中报道的不同突变/多态性及其与血栓形成风险的关联。